Stoke Therapeutics, Inc. Increase (Decrease) in Accounts Receivable
Stoke Therapeutics, Inc. (STOK) reported Increase (Decrease) in Accounts Receivable of $1.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-03
- Stoke Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $2.73M.
- Stoke Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$1.49M, a 212.15% decline year-over-year.
- Stoke Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$3.31M.
- Stoke Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $11.33M.
- Stoke Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2025 was $4.27M, a 8436.00% increase from fiscal 2024.
- Stoke Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2024 was $50.00K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $1.24M 10-Q · filed 2026-08-03 | -$2.07M derived: sum of 3 quarters · filed 2026-08-03 | $9.26M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$1.49M 10-Q · filed 2026-05-07 | -$4.80M derived: sum of 2 quarters · filed 2026-05-07 | $6.54M derived: sum of 3 quarters · filed 2026-05-07 | $1.46M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$3.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $8.02M derived: sum of 2 quarters · filed 2026-03-16 | $2.94M derived: sum of 3 quarters · filed 2026-08-03 | $4.27M 10-K · filed 2026-03-16 |
| 2025-09-30 | $11.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $6.25M derived: sum of 2 quarters · filed 2026-08-03 | $7.58M 10-Q · filed 2025-11-04 | $7.28M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$5.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$3.75M 10-Q · filed 2026-08-03 | -$4.05M derived: sum of 3 quarters · filed 2026-08-03 | |
| 2025-03-31 | $1.32M 10-Q · filed 2026-05-07 | $1.03M derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2024-12-31 | -$298.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $50.00K 10-K · filed 2026-03-16 | ||
| 2024-09-30 | $348.00K 10-Q · filed 2025-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |